Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.

Revenue projections:

Revenue projections for APLLTD
Revenue projections for APLLTD

APLLTD is projected to see lower revenues than in the previous year, a trend that usually concerns investors. Declining revenues often harm a company's profitability, leading investors to exercise caution as they weigh the potential risks of continued financial downturns.

Financial Ratios:

currentRatio 1.69500
forwardPE 21.12319
debtToEquity 24.23200
earningsGrowth -0.12000
revenueGrowth 0.16700
grossMargins 0.73121
operatingMargins 0.11468
trailingEps 29.65000
forwardEps 43.50000

APLLTD's current ratio being 1.695 suggests that the company has no issue servicing its short-term debt. Its strong liquidity position, supported by sufficient cash reserves and current assets, ensures that APLLTD can meet its financial obligations with ease.
Alembic Pharmaceuticals Limited's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
Alembic Pharmaceuticals Limited's low Debt-to-Equity ratio indicates that the company isn't heavily dependent on debt financing. This lower leverage reduces financial risk and enhances stability, showing that Alembic Pharmaceuticals Limited is well-positioned to manage its obligations without the burden of excessive debt.
APLLTD's low growth in earnings and revenue indicates a potential decline in profits. This suggests that the company could be facing financial challenges, making it harder to sustain its current profit margins.
Alembic Pharmaceuticals Limited's negative gross and operating margins indicate that the company is currently unprofitable at both the production and operational levels. This suggests significant challenges in managing costs and generating revenue, which could impact its overall financial health.
Alembic Pharmaceuticals Limited's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that Alembic Pharmaceuticals Limited's financial performance will improve in the current financial year.

Price projections:

Price projections for APLLTD
Price projections for APLLTD

Alembic Pharmaceuticals Limited's stock price has consistently been near the lower edge of expected values, indicating potential struggles in meeting growth projections. This trend may reflect a cautious market sentiment toward the company.

Insider Transactions:

Insider Transactions for APLLTD
Insider Transactions for APLLTD


Alembic Pharmaceuticals Limited saw 11 buy transactions, with market price of 835.5045443448154.During the review period, no buy transactions were executed.APLLTD has seen more sells at current price levels, which could indicate a potential decline. If this trend continues, investors may expect the stock's price to drop further as more people exit their positions.

Recommendation changes over time:

Recommendations trend for APLLTD
Recommendations trend for APLLTD


Analysts' buy bias for Alembic Pharmaceuticals Limited signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to Alembic Pharmaceuticals Limited, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.